An­ti­body leg­end Till­man Gern­gross is el­bow­ing his way in­to the Covid-19 R&D cru­sade: 'I don’t see this end­ing any­time soon'

Last year
Startups
Bioregnum

A neoanti­gen pi­o­neer says its tech is work­ing great. So what wrecked the share price?

Last year
Bioregnum
Opinion

A top an­a­lyst turns the spot­light on Mod­er­na, fu­el­ing a fast-and-fu­ri­ous Street race over the fu­ture of mR­NA

Last year
Bioregnum
Coronavirus

Win or lose on the mar­ket­ing OK, the FDA just gunned down GSK’s bright hopes for their BC­MA ther­a­py

Last year
Bioregnum
FDA+

The home run count: The $100M+ mega-round boom in biotech in­spired a $7.3B feed­ing fren­zy — so far this year

Last year
Bioregnum
R&D

A new study points to $6.5B in pub­lic sup­port build­ing the sci­en­tif­ic foun­da­tion of Gilead­'s remde­sivir. Should that be re­flect­ed in the price?

Last year
Bioregnum
R&D

Which drug de­vel­op­ers of­fer Trump a quick, game-chang­ing ‘so­lu­tion’ as the pan­dem­ic roars back? Eli Lil­ly and Ab­Cellera look to break out of the pack

Last year
Bioregnum
Pharma

Day one: The dis­rup­tor-in-chief at Bridge­Bio in­vites Brent Saun­ders on­to the board

Last year
People
Bioregnum

What’s it take to raise $700M-plus for a biotech start­up? Steve Harr has some thoughts on that

Last year
Financing
Cell/Gene Tx

Two Bay Area up­starts out to de­liv­er on cell ther­a­py 2.0 join forces on a quest: pur­su­ing a Holy Grail in on­col­o­gy R&D

Last year
Deals
Cell/Gene Tx

The FDA backs off a hasty — and dam­ag­ing — emer­gency OK for a po­ten­tial­ly dan­ger­ous Covid-19 drug

Last year
Bioregnum
R&D

A pi­o­neer­ing im­muno-on­col­o­gy re­searcher heads back to Dana-Far­ber as Eli Lil­ly’s can­cer R&D group un­der­goes a wrench­ing change­up

Last year
People
R&D

When times got tough, the bio­phar­ma in­dus­try hit the Zoom but­ton and kept things mov­ing at a multi­bil­lion-dol­lar clip

Last year
Deals

Cameron Dur­rant hus­tled his way from the OTC side­lines right in­to the Covid-19 drug race. Death or glo­ry lies straight ahead

Last year
People
Bioregnum

Is a pow­er­house Mer­ck team prepar­ing to leap past Roche — and leave Gilead and Bris­tol My­ers be­hind — in the race to TIG­IT dom­i­na­tion?

Last year
R&D

The big mon­ey: Poised to make drug R&D his­to­ry, a Chi­na biotech un­veils uni­corn rac­ing am­bi­tions in a bid to raise $350M-plus on Nas­daq

Last year
Financing
China

Macro­Gen­ics CEO Scott Koenig gets the pre-AS­CO par­ty start­ed with some en­cour­ag­ing pipeline tid­bits — leav­ing lots of ques­tions for lat­er

Last year
Bioregnum
R&D

Deal­mak­ing spiked to record lev­els in April as Covid-19 trig­gered a fever of part­ner­ing. But what hap­pens to col­lab­o­ra­tions in a new world seen through Zoom?

Last year
Deals

Full steam ahead, Pfiz­er goes bar­gain hunt­ing in an age of coro­n­avirus — with a spe­cial fo­cus on can­cer and rare dis­eases

Last year
Bioregnum
R&D

A slice of half-baked remde­sivir da­ta takes a dark turn — but we're still wait­ing for a de­fin­i­tive study

Last year
Bioregnum
R&D

Bio­gen’s top ex­ec­u­tive crew has a big cred­i­bil­i­ty is­sue. And they seem de­ter­mined to make it worse

Last year
People
Bioregnum

Piv­otal da­ta ce­ment use of In­cyte, No­var­tis' rux­oli­tinib in dif­fi­cult-to-treat graft-ver­sus-host dis­ease

Last year
R&D
Pharma

Still no ad­u­canum­ab fil­ing and an in-house gath­er­ing trig­gered a health dis­as­ter, but Bio­gen's CEO nev­er­the­less took home record pay

Last year
People

Nat­ur­al killers are com­ing for Covid-19 and the ther­a­py, ex­perts say, could make things worse

Last year
R&D
Coronavirus
First page Previous page 6789101112 Next page Last page